Objective To report on the routine clinical implementation of cell-free DNA (cfDNA) analysis of maternal blood for trisomies 21, 18 and 13, contingent 
INTRODUCTION
In singleton pregnancy, screening for the major trisomies using a combination of fetal nuchal translucency (NT) thickness, serum β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) can detect about 90% of cases of trisomy 21, 18 or 13, at a false-positive rate (FPR) of 5% 1, 2 . In twin pregnancy, use of the combined test can achieve a similarly high detection rate (DR) for trisomy 21 as in singletons, but with a higher FPR of about 6% 3 . A more effective method of screening for trisomy 21 is provided by analysis of cell-free DNA (cfDNA) in maternal blood; a recent meta-analysis of clinical validation studies reported that, in the combined total of 1963 cases of trisomy 21 and 223 932 of non-trisomy-21 singleton pregnancies, the weighted pooled DR and FPR were 99.7% (95% CI, 99.1-99.9%) and 0.04% (95% CI, 0.02-0.07%), respectively 4 . In twin pregnancies, the performance of screening for trisomy 21 by cfDNA is encouraging, but the number of cases reported is small; in a total of 24 cases of trisomy 21 and 1111 non-trisomy-21 cases, the DR was 100% (95% CI, 95.2-100%) and FPR was 0.0% (95% CI, 0.0-0.003%), respectively 4 .
In screening for the major trisomies in the general population, cfDNA testing can be used either as a first-line method of screening or contingent on the results of the combined test at 11-13 weeks' gestation. Contingent screening could potentially lead to a very high DR and very low invasive testing rate at a considerably lower cost than would be possible using cfDNA testing as a first-line method of screening, based on current cfDNA testing costs 5, 6 . We have reported previously on the clinical implementation of such a policy in singleton pregnancies 7, 8 .
The objective of this study was to examine the clinical implementation of cfDNA testing, contingent on the results of the combined test, in routine first-trimester screening for fetal trisomies in twin pregnancies.
METHODS

Study design and participants
This was a prospective study in women with a twin pregnancy attending one of two National Health Service (NHS) hospitals in England (King's College Hospital, London, and Medway Maritime Hospital, Kent) for routine care between October 2013 and January 2018. Implementation of contingent screening was approved by the National Research Ethics Committee (REC reference: 13/LO/0885).
During a routine visit at 11-13 weeks' gestation, we recorded maternal demographic characteristics and medical history, measured maternal serum free β-hCG and PAPP-A (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA) and carried out an ultrasound scan to determine gestational age from the measurement of the fetal crown-rump length 9 of the larger fetus, and chorionicity by examining the junction of the intertwin membrane with the placenta 10 , to diagnose any major fetal abnormalities and measure fetal NT thickness. The measured NT thickness was expressed as a difference from the expected normal mean for gestation (delta value) 11 . Similarly, the measured free β-hCG and PAPP-A were converted into multiples of the median values adjusted for maternal characteristics, gestational age and chorionicity 3, 12 . The estimated risk for trisomy 21 and that for trisomy 18 or 13 were calculated. In the case of monochorionic twins, a risk was given for the whole pregnancy; in dichorionic twins a risk was given for each fetus and the highest of the two was used for stratification. Women in the high-risk group (risk ≥ 1 in 100) were offered the option of chorionic villus sampling (CVS), cfDNA testing or no further testing; this cut-off was selected because it is used by the NHS for offering invasive testing. Women in the intermediate-risk group (risk 1 in 101 to 1 in 2500 in the first phase of the study and 1 in 101 to 1 in 500 in the second phase) were offered cfDNA or no further testing. Women in the low-risk group (risk < 1 in 2500 in the first phase of the study and < 1 in 500 in the second phase) were reassured that fetal trisomy was unlikely and no further testing was necessary.
Women provided written informed consent and maternal blood (20 mL) was sent via courier to the USA for cfDNA testing (Harmony™ Prenatal Test, Ariosa Diagnostics, Inc., San Jose, CA, USA) 13, 14 . Digital analysis of selected regions (DANSR) by chromosome-selective sequencing or microarray was used to quantify chromosomes 21, 18 and 13. Risk scores for trisomies 21, 18 and 13 were provided as a percentage with ranges capped at > 99% and < 0.01%. In cases in which the cfDNA test did not provide results, the parents were offered repeat testing or to rely on the results of the combined test in deciding whether to have an invasive test or not. In cases with a high-risk result from the cfDNA test, the parents were advised to consider having invasive fetal karyotyping before deciding on the further management of their pregnancy.
Patient characteristics, results of the investigations and pregnancy outcome were recorded in a database. The outcomes were divided into, first, trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood demonstrated the relevant trisomy in one or both fetuses, second, no trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood was normal or both neonates were phenotypically normal, third, no known karyotype in both fetuses because the pregnancy resulted in termination or embryo reduction, miscarriage or stillbirth and no karyotyping of fetal tissue was carried out, and, fourth, outcome unknown because the pregnancy was lost to follow-up.
Statistical analysis
Descriptive data are presented as median and interquartile range (IQR) for continuous variables and as number and percentage for categorical variables. Comparisons between outcome groups were by Mann-Whitney U-test for continuous variables and χ 2 test or Fisher's exact test for categorical variables.
The statistical software package R version 3.3.3 (https:// www.R-project.org/) was used for data analyses.
RESULTS
Study population
During the study period, 977 women with a twin pregnancy and two live fetuses at 11-13 weeks' gestation were offered combined screening for trisomies; 959 (98.2%) accepted, but 42 (4.4%) of these were excluded from further analysis either because the pregnancy ended in termination, miscarriage or stillbirth with no known karyotype (n = 29) or they were lost to follow-up (n = 13).
Maternal and pregnancy characteristics of the 917 pregnancies with known trisomic status of both twins are summarized in Table 1 ; these included 740 (80.7%) dichorionic and 177 (19.3%) monochorionic twins. In the monochorionic twin pregnancies, there were no trisomic fetuses. In the dichorionic twin pregnancies, there were 10 in which one fetus was normal and the cotwin was trisomic (six cases of trisomy 21 and four of trisomy 18). On the basis of the maternal age distribution and the age-related risk for these trisomies at 12 weeks' gestation, the expected numbers of cases of trisomy 21 and trisomy 18 or 13 in our monochorionic twin pregnancies were 0.6 (95% CI, 0.07-4.87) and 0.3 (95% CI, 0.02-4.32), respectively 15, 16 . In the dichorionic twin pregnancies, on the assumption that the trisomic risk for each of the 1480 fetuses was the same as that in singleton pregnancies, the expected numbers of cases of trisomy 21 and trisomy 18 or 13 in our study population were 6.4 (95% CI, 3.03-13.54) and 3.4 (95% CI, 1.26-9.32), respectively, which were similar to the observed numbers of six and four, respectively 15, 16 . 
Stratification of risk and parental choice
Results of combined test
Combined screening with an estimated risk cut-off of 1 in 100 detected 83.3% (5/6) of cases of trisomy 21 and 75% (3/4) with trisomy 18. One case of trisomy 21 had a risk of 1 in 939 and this was identified by cfDNA testing. In three of the six cases of trisomy 21, the parents chose to continue with the pregnancy and, in the other three, they had embryo reduction. One case of trisomy 18 had a risk of 1 in 3450 and this case was identified by amniocentesis because, at the routine 20-week scan, the affected fetus had tetralogy of Fallot, clenched hands, strawberry-shaped head and growth restriction.
Implementation and performance of cfDNA test
In total, the cfDNA test was carried out in 224 pregnancies. These included 213 from the highand intermediate-risk groups that opted for cfDNA testing and 11 from the high-risk group that opted for CVS but also had cfDNA testing for research; in the latter group, the blood test was collected before invasive testing. Results from testing were provided after first sampling for 95.5% (214/224) of cases and the median fetal fraction was 8.5% (range, 4-30%). The reasons for no result were insufficient fetal cfDNA for accurate evaluation in seven cases and that the sample did not meet thresholds for quality control in three. In seven of the 10 cases with no result, a further blood sample was obtained and a cfDNA result was provided in one. In eight of the nine cases with no result from the cfDNA test, the parents decided to avoid further testing, and in one the parents chose to have amniocentesis.
The group of 215 pregnancies with a cfDNA result (214 from first sampling and one from second sampling) included six with trisomy 21, three with trisomy 18 and 206 with no trisomy 21, 18 or 13. The cfDNA test classified correctly as screen positive all six cases of trisomy 21 and two of the three with trisomy 18, and as screen negative for each of the trisomies all 206 unaffected pregnancies.
The distribution of estimated risk for trisomies by the combined test and the cfDNA test is given in Figure 1 .
Performance of contingent screening
The study population of 917 pregnancies with known trisomic status of both twins included six with trisomy 21, four with trisomy 18 and 907 with no trisomy 21, 18 or 13. Contingent screening led to prenatal detection of all cases of trisomy 21 and three of four with trisomy 18 (one case was classified as low risk by the combined test).
Invasive tests were carried out in 33 (3.6%) pregnancies in the study population. These included 17 (51.5%) for high-risk result from the combined test, two (6.1%) for positive result from the cfDNA test, one (3.0%) for failed cfDNA testing, five (15.2%) for fetal defects detected by ultrasound examination in the second trimester of pregnancy, seven (21.2%) for endoscopic laser separation of communicating placental vessels in association with severe twin-twin transfusion syndrome or selective fetal growth restriction, and one (3.0%) for prenatal diagnosis of sickle cell disease.
DISCUSSION
Principal findings
This study has demonstrated the feasibility of introducing cfDNA testing, contingent on the results of the first-trimester combined test for major trisomies, in a routine population of twin pregnancies. The observed number of trisomies was as expected on the basis of the maternal age distribution of the study population.
In our participating hospitals, about 98% of women attending for a routine ultrasound examination at 11-13 weeks' gestation accepted the offer of screening for fetal trisomies by the combined test and this was carried out successfully in all cases. In the high-risk group, 36% of women opted for invasive testing, 57% for cfDNA testing and 6% for no further tests; in the subgroup with risk of ≥ 1 in 30, 56% opted for invasive testing. In the intermediate-risk group, 92% opted for cfDNA testing and 8% for no further tests. These results of patient choice are very similar to those reported in our previous study on singleton pregnancies 8 . In the high-risk group, the choice between CVS and cfDNA testing was influenced by objective evidence derived from the patient-specific risk obtained from the combined test. In three of the six cases of trisomy 21, the parents chose to continue with the pregnancy and, in the other three, they had embryo reduction; there were no obvious differences between the two groups in terms of maternal age, race, parity or method of conception.
The combined test, at risk cut-off of 1 in 100, could have potentially identified five of six cases of trisomy 21 and three of four of trisomy 18, at a FPR of 4.3%. The number of affected cases is too small for accurate assessment of the performance of screening, but the results are consistent with the modelled performance of about 90% detection of the major trisomies at a FPR of 6% 3 . In the group undergoing cfDNA testing, results were provided for 96% of pregnancies; the failure rate in twin pregnancies was twice as high as that in our previous study on singleton pregnancies 8 . The cfDNA test detected all cases of trisomy 21 and two of three with trisomy 18 in the population having this test, at a FPR of 0%. As in the case of the combined test, the number of affected cases is too small for accurate assessment of the performance of cfDNA screening, but the results are consistent with those of previous reports [17] [18] [19] [20] [21] [22] [23] [24] .
Limitations
The main limitation of the study relates to the small number of trisomic pregnancies and the small number of cases that had cfDNA testing, preventing definitive conclusions being drawn in terms of performance of screening by these two methods.
The results on the uptake of various options of screening and management of affected pregnancies depending on risk categories defined by the combined test highlight some general principles concerning the factors that influence patient decisions. However, the exact rates of uptake of a specific option may not be generalizable to all populations from different racial and socioeconomic backgrounds in different countries and healthcare systems.
Previous studies of cfDNA testing in twin pregnancies
There are only seven prospective studies with complete follow-up reporting on the performance of cfDNA testing in twin pregnancies [18] [19] [20] [21] [22] [23] [24] . Two studies examined a routine population 23, 24 , three examined pregnancies at high-risk of aneuploidy [20] [21] [22] , and two were in a mixed population of high-and low-risk pregnancies 18, 19 . In the combined total of 31 cases of trisomy 21 and 2008 non-trisomic pregnancies, the detection rate was 100% and FPR was 0.05%. Although the number of twin pregnancies examined by cfDNA testing is considerably lower than that for singleton pregnancies 4 , the results suggest the test is equally effective in identifying trisomy 21.
Conclusions
Clinical implementation of cfDNA testing contingent on the results of a previously performed first-trimester combined test is feasible and it could potentially lead to the prenatal detection of a higher proportion of affected pregnancies and a lower invasive-testing rate than in screening by the combined test alone. However, in clinical practice, prenatal detection of trisomies and pregnancy outcome depend not only on the performance of screening tests but also on parental choice. Consequently, clinical implementation of cfDNA testing contingent on the results of the combined test may have only a modest impact on reducing the rate of invasive testing and a small effect on the rate of live births with trisomy 21.
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Cribado rutinario en el primer trimestre para trisomías fetales en el embarazo de gemelos: prueba de ADN fetal en función de los resultados de una prueba combinada RESUMEN Objetivo Informar sobre la aplicación clínica rutinaria del análisis de ADN fetal (cfDNA, por sus siglas en inglés) en la sangre materna para las trisomías 21, 18 y 13, en función de los resultados de la prueba combinada del primer trimestre en el embarazo gemelar.
Métodos Se llevó a cabo un cribado para las trisomías 21, 18 y 13 en 959 embarazos gemelares mediante la evaluación de una combinación de edad materna, grosor de la translucencia nucal del feto, y la ausencia en suero de la hormona gonadotrópica coriónica humana (subunidad B) y la proteína plasmática A asociada al embarazo a las 11-13 semanas de gestación en dos hospitales del NHS del Reino Unido. A las mujeres del grupo de alto riesgo (riesgo ≥1 en 100) se les ofreció la opción de realizar pruebas invasivas, la prueba de cfDNA o no realizar más pruebas, y a las del grupo de riesgo intermedio (riesgo 1 en 101 a 1 en 2500 en la primera fase del estudio y 1 en 101 a 1 en 500 en la segunda fase) se les ofreció la prueba de cfADN o no realizar más pruebas. El estado trisómico de los embarazos se determinó mediante el cariotipo prenatal o postnatal o el examen de los recién nacidos.
Resultados En 42 (4,4%) de los 959 embarazos, hubo interrupción, aborto oéxitus fetal sin cariotipo conocido o no se hizo seguimiento. Los 917 embarazos con estado trisómico conocido de ambos gemelos incluyeron seis que eran discordantes con la trisomía 21, cuatro que eran discordantes con la trisomía 18 y 907 sin trisomía 21, 18 o 13. Tras el cribado combinado, 47 (5,1%), 203 (22,1%) y 667 (72,7%) de los embarazos se clasificaron como de alto riesgo, riesgo intermedio y bajo riesgo, respectivamente. El grupo de alto riesgo incluyó cinco (83,3%) casos de trisomía 21 y tres (75,0%) de trisomía 18. La prueba de cfDNA se realizó en 224 embarazos y se obtuvieron resultados de 214 (95,5%) de ellos; este grupo incluyó seis embarazos con trisomía 21, tres con trisomía 18 y 206 sin trisomía 21, 18ó 13. La prueba de cfDNA clasificó correctamente como positivo en los seis casos de trisomía 21 y dos de los tres con trisomía 18, y como negativo en cada una de las trisomías en los 206 embarazos no afectados. El cribado contingente dio lugar a la detección prenatal de todos los casos de trisomía 21 y tres de los cuatro con trisomía 18.
Conclusión Este estudio ha demostrado la factibilidad de introducir la prueba de cfDNA, contingente con los resultados de la prueba combinada del primer trimestre para trisomías principales, en una población rutinaria de embarazos gemelares.
